Educational aims

- To illustrate the common signs of cognitive impairment and define potential associations between lung and cognitive dysfunction.
- To illustrate the potential influence of cognitive deficits on the optimal progress of respiratory therapy.
- To illustrate the importance of cognitive evaluation as part of a comprehensive clinical assessment for patients suspected of suffering cognitive impairment.
Cognitive impairment in COPD: should cognitive evaluation be part of respiratory assessment?

Cognitive impairment is highly prevalent in patients with COPD and demonstrates multiple detrimental effects on many aspects of patient state and therapeutic outcomes. It is attributed to several overlapping pathophysiological factors, with the most common being the low level of oxygen saturation due to respiratory insufficiency. Despite the impact of cognitive impairment on clinical outcomes, the screening for coexisting cognitive deficits which may interfere with the successful progress of respiratory treatment is yet neglected. There is a special consideration that cognitive deficits should be taken into account when developing respiratory therapy plans. Cognitively impaired patients are likely to require more support and have need of an individualised respiratory care plan which can also be beneficial for their cognitive deficits. Pulmonary rehabilitation as a multidisciplinary approach could be prioritised for COPD patients with cognitive impairment.

Introduction

Chronic obstructive pulmonary disease (COPD) is characterised by persistent respiratory symptoms and airflow limitation [1]. It is a progressive condition which is associated with pulmonary and systemic inflammation with numerous extrapulmonary consequences such as cognitive deterioration [2]. In particular, the brain can be vulnerable to the systemic effects of COPD as several features of the disease may increase the risk for impaired cognitive function and also contribute to cognitive decline across the progress of disease severity and the ageing process [3]. Cognitive impairment is characterised by several common signs (table 1) and seems to have detrimental effects on many aspects of patient function, health status and quality of life, as well as being related to lower adherence to medical treatment and increased rates of hospitalisation and mortality in COPD [4–6]. A growing amount of evidence has demonstrated an association between cognitive impairment, a pathological condition that acts as a barrier to cognition, and COPD manifestation [7, 8]. Indeed, the prevalence estimates of cognitive impairment are increased in patients with COPD, indicating lung dysfunction as a risk factor for cognitive impairment even when data are adjusted for age, sex, smoking habits and education level [9]. The degree of prevalence ranges from 10 to 61% amongst COPD patients and seems to depend on the study population and the method of neuropsychological
Cognitive impairment in COPD

The prevalence amongst older adults in the general population, as assessed in community samples, seems to be lower with between 3 and 20% having cognitive deficits depending on the way that cognitive function is assessed [11, 12]. On average, 36% of patients with COPD will present with incidents of cognitive impairment [8], whereas only 12% of individuals amongst the general population [13] will be cognitively impaired. These higher prevalence estimates for cognitive impairment in COPD indicate an association between impaired lung function and brain pathology that cannot be disputed. Nevertheless, defining all the complex pathophysiological mechanisms in COPD that may interfere with brain function is really challenging. Lung dysfunction and disease severity in COPD do not fully explain the development of cognitive impairment in COPD patients. Moreover, the typical profile of patients with COPD includes numerous of comorbidities, such as cardiovascular disease or diabetes or a combination thereof (so called “multimorbidity”), which may contribute to the genesis of cognitive impairment to a varying extent [14, 15]. In addition, the impact of disease severity (including comorbidities or other risk factors) can affect different domains of cognition variably, with some being unaffected while others present substantial impairment.

Cognition and neuropsychological domains

The word “cognition” is of Latin derivation but originally comes from the Greek verb “gignosko” which means to recognise, perceive and know [16]. Specifically, cognition is the mental action or intellectual process of acquiring, understanding and using knowledge or information, through thinking, experience and the senses, by which human behaviour can be adapted to new situations and/or preferences changed [17, 18]. Cognition involves different cognitive processes which can be divided into six basic neuropsychological domains including learning and memory, visuospatial and motor function, attention/concentration, language, social cognition/emotions and executive functions (figure 1). Each domain contains specific functions which provide individuals with basic and more complex capabilities that determine personal intellectual skills and knowledge (figure 1) [18, 19].

Assessment of cognitive function

Cognitive function can initially be assessed without complex procedures or sophisticated equipment. Using appropriately validated screening tests for cognitive impairment, healthcare professionals may obtain a first overview of the cognitive status of a patient, as inferred from the relationship of the patient’s score to reference norms. Patients with very low screening scores can be considered as cognitively impaired and may therefore be referred to a mental health clinic, whereas patients with borderline scores may be referred for further comprehensive assessment by a specialist with expertise in evaluating mental function [20]. A borderline score may identify patients in the first stages of cognitive decline, which is defined as mild cognitive impairment (MCI), differentiating patients who have worse cognitive deficits than those expected in normal ageing but not severe enough to warrant a diagnosis of dementia [21].

A wide range of tools has been developed for screening cognitive function. Some of them are freely available whereas for others a licence is required. These tools can be described as comprehensive when they cover each of the primary cognitive domains in cognitive function (figure 1) or non-comprehensive when they identify clinically significant levels of cognitive impairment across a limited spectrum of cognitive abilities [22]. The duration of screening ranges from a few minutes up to several hours in the case of a formal neuropsychological assessment [20]. Most of the tests designed for use in prompt cognitive evaluation during the daily clinical routine take

| Table 1 Signs of cognitive impairment: several symptoms may imply a cognitive dysfunction in patients with chronic obstructive pulmonary disease (COPD) |
|---|
| Memory loss that is unusually frequent for the age of the patient |
| Frequent word-finding pauses or substitutions |
| Frequently asking the same question or repeating the same story over and over again |
| Inability to recognise familiar people and places and lack of orientation |
| Trouble in exercising judgment and taking actions |
| Changes in mood or behaviour which are not conscious, isolation or misbehaviour |
| Trouble judging distances and seeing objects properly (not caused by poor eyesight) |
| Problems in completing step-by-step tasks and loss of executive function (planning, organising, reasoning) |
from 4 to 12 min to be completed. The most widely-used tests which cover multiple cognitive domains are the Mini Mental State Examination (MMSE) [23], the Addenbrooke’s Cognitive Examination (ACE) [24, 25], the Montreal Cognitive Assessment (MoCA) [26], the Clock Drawing Test (CDT) [27] and the Mini-Cog test [28]. In addition, telephone interviews have been developed for use in distance situations where in-person cognitive screening is impractical or impossible [29, 30]. These tests have good diagnostic accuracy [31] and can provide healthcare professionals with a prompt overview of patients’ cognitive status when cognitive impairment is suspected.

**Lung impairment and cognitive function**

Cognitive function refers to the general competence of cognitive abilities that can be affected by COPD pathophysiology. The relationship between lung impairment and cognitive function decline has already been confirmed in numerous studies, which have demonstrated the particularly negative impact of inadequate respiratory function on cognitive domains such as memory and learning, attention, psychomotor speed, visuospatial abilities, executive functions, and language skills [32–34]. These negative consequences on cognitive function are a result of complex interactions amongst COPD pathophysiological, genetic and environmental factors.

The most obvious independent risk factor for cognitive impairment in patients with COPD is reduced oxygen availability as a result of lung dysfunction. From a physiological point of view it is reasonable to consider that the brain, which has almost the highest oxygen demand of any organ in the human body (the biggest oxygen consumers are the liver (20.4%), the brain (18.4%), and the heart (11.6%)) [35], is highly sensitive and exposed to ischaemic damage. If oxygen supply is insufficient to meet the metabolic demands of the brain due to impaired lung mechanics or inadequate respiratory function in COPD patients, this can trigger the loss of vulnerable cerebral neurons [36].
Therefore, arterial hypoxia seems to be a major contributor to cognitive impairment with higher levels of oxygen desaturation increasing the risk of cognitive dysfunction [37]. Moreover, lower cognitive performance has been found to be related to elevated carbon dioxide tension ($P_{CO_2}$) and the occurrence of hypercapnia at rest or during activity [38, 39]. Evidence has shown that increased $P_{CO_2}$ is related to lower reaction times, delayed memory, slower information processing speed, and deficits in attention and concentration [40]. Also, study data has demonstrated that chronic hypoxia–hypercapnia can negatively affect patients’ cognitive function including some distinctive patterns of cognitive dysfunction [41]. In addition, Liesker et al. [42] have observed that overall cognitive impairment is significantly worse in both hypoxaemic and non-hypoxaemic COPD patients when compared to healthy individuals. Also, the overall relationship between $P_{CO_2}$ and cognitive impairment is even less clear when compared to low levels of oxygen. Van de Ven et al. [43] did not find abnormal cerebrovascular responses to carbon dioxide in hypercapnic patients with COPD and hypoxaemia or hypercapnia alone are not enough to entirely account for the observed cognitive deficits in patients with COPD. Additional risk factors that are not directly related to lung function could therefore be potential contributors to cognitive impairment in COPD.

**Risk factors for cognitive impairment in COPD**

Besides lower oxygen and/or higher carbon dioxide levels in blood, a complex interaction between pulmonary and non-pulmonary risk factors may account for COPD-related cognitive deficits [18]. According to the literature, other major risk factors which may potentially be associated with cognitive impairment are: 1) the presence of increased inflammation and oxidative stress [44, 45]; 2) reduced physical activity [46, 47]; 3) peripheral vascular disease [48]; 4) high or low blood pressure (non-normotensive patients) [49, 50]; 5) increased intracranial pressure associated with the narrowing of blood vessels in the brain [51]; 6) coexisting comorbidities [52]; 7) tobacco smoking [53]; and 8) genetic predisposition [54].

The pathophysiological mechanisms which link these risk factors with cognitive impairment are not clearly understood. It appears that there is a general concept that increased inflammation and oxidative stress, as well as the lack of physical activity, can express the ageing process and, therefore, increase age-related neurodegenerative changes [55]. Moreover, vascular disturbances leading to systemic hypertension or increased intracranial pressure are a risk factor for ischemic cortical infarcts [56]. On the other hand, systemic hypotension, which seems to be related to cerebral hypoperfusion in response to the reduced blood flow often caused by increased medication, may be responsible for protein synthesis abnormalities and reduced oxygen availability resulting in neurodegenerative lesions [57]. Moreover, reduced tonic cortical arousal related to hypoperfusion may contribute to lower cognitive performance [58]. Coexisting comorbidities that contribute to overall lung disease severity [59] and tobacco smoking, which appears to modulate brain function through nicotine [53], may also be accountable for cognitive dysfunction. Furthermore, genetic abnormalities are a major contributor to cognitive disability [60]. Several risk factors for cognitive deterioration, both with an independent impact and with overlapping contributions towards the development of cognitive impairment, are illustrated in Figure 2.

**Should cognitive function be evaluated in the initial respiratory assessment?**

Cognitive impairment has a negative impact on the personal characteristics of COPD patients including psychological profile, conscientiousness and the general ability to communicate and understand. The prevention of cognitive impairment by early intervention is thus important for treating, delaying or postponing its underlying processes and dealing with potential functional impairments that can act as barriers to the therapeutic management of COPD [61]. Specifically, cognitive deficits can result in an inability to accurately perform given instructions in respiratory examinations, such as in spirometry where several respiratory manoeuvres are included. A concerning issue then arises, as this could result in erroneous estimations of lung function capacity and potential misdiagnosis of the stage of disease severity in COPD [62]. Similarly, these patients may not understand the meaning of maximal exercise tests resulting in lower effort and underestimation of their exercise performance [63]. Moreover, cognitive impairment may be held responsible for insufficient adherence to therapeutic modalities and/or to medication and this is costly. The lack of adherence to a therapeutic strategy is a significant obstacle in optimal management of COPD and results in increased rates of morbidity, healthcare expenditure, and hospitalisation, as well as increased risk of mortality, unnecessary escalation of therapy and poorer quality of life [64]. Evidence has shown that an average of 40 to 60% of patients with COPD are committed to the prescribed regimen while only 1 in 10 patients with a metered-dose inhaler perform all of the essential steps correctly [65]. Communication problems and/or misunderstandings between patient and doctor may also result in refusal of treatment [66]. Forgetting or refusing to take a prescribed dose is usually the most frequent cause of non-adherence [67]. Furthermore, COPD patients with
cognitive impairment may exhibit more functional
dependence during a pulmonary rehabilitation
programme and gain less benefits from it compared
to cognitively intact counterparts [68].

Taking into account all the aforementioned
issues, it is reasonable to conclude that cognitive
function should be part of the initial respiratory
assessment, especially for those patients presenting
evident or self-reported symptoms of cognitive
deficit, preferably corroborated by a close-informant
[69]. Cognitive function also deserves particular
attention in older patients (>65 yrs) at high risk,
such as COPD patients with hypoxaemia, increased
inflammation and coexisting comorbidities. Therefore,
healthcare professionals who deal with elderly COPD patients are advised to be
skilled in administering at least one brief cognitive
test to a patient when cognitive impairment is
suspected [70]. Timely detection of mild cognitive
impairment (MCI) and awareness of this disorder is
of great importance as actions can be taken to
minimise or even to reverse cognitive decline and its
consequences, and identify patients with increased
risk of developing dementia.

Treatment of cognitive impairment as part of respiratory care

The goal of COPD management is to improve
a patient’s functional status by preserving
optimal lung function and to improve quality of
life by mitigating the symptoms of disease and
preventing secondary complications or recurrence
of exacerbations [1]. However, the high prevalence of cognitive impairment in patients with COPD, in association with the detrimental consequences of cognitive deficits on functional status and quality of life, may indicate that action should be taken
towards dealing with cognitive impairment within
the frame of respiratory treatment. According to
the literature there are some modifiable factors,
such as physical activity [71, 72], balanced diet [73],
cognitive training [74] and social engagement [75],
that can be improved to provide beneficial effects to
patients with COPD who have presented evidence of cognitive impairment.

Pulmonary rehabilitation as a multidimensional programme of exercise and education can be highly
recommended for COPD patients with cognitive
impairment [76]. The exercise programmes
implemented during pulmonary rehabilitation,
along with nutritional support, have been
recommended as effective strategies to counteract
neurological and cognitive disorders [77]. In
addition, pulmonary rehabilitation provides
patients with the opportunity to establish social
contacts, obtain support and sympathy, and
interact with, encourage, and motivate the other
participants [78]. Pulmonary rehabilitation has also
been found to reduce symptoms of depression and
anxiety in COPD patients [79,80,81]. All these
aforementioned favourable effects can be very
promising for cognitively impaired patients with
COPD. Indeed, Pereira et al. [82] have investigated
the effects of pulmonary rehabilitation on cognitive
function in patients with COPD and have reported
significant improvements in cognitive performance.
Cognitive impairment in COPD

Educational questions

1. Regarding the impact of lung impairment on cognitive function in COPD, which of the following is true?
   a) COPD patients with cognitive impairment present disadvantageous cognitive deficits in all the major cognitive domains.
   b) COPD patients with cognitive impairment present profound cognitive deficits, primarily on memory ability, even though they are able to provide detailed examples of forgetfulness.
   c) COPD patients developing cognitive impairment present cognitive deficits in at least one cognitive domain, whilst the rest of the domains can be unaffected.
   d) COPD patients developing cognitive impairment may only occasionally present cognitive deficits in several cognitive domains.

2. What is the major problem related to cognitive impairment in respiratory assessment?
   a) Patients’ forgetfulness and inability to understand instructions for the ongoing management of their disease may cause delays and act as a barrier to therapeutic management.
   b) Communication problems or memory deficits due to cognitive impairment may result in misleading information being provided to healthcare professionals by patients.
   c) Communication problems between patients and healthcare professionals may limit the application of important tests during respiratory assessment.
   d) Patients’ inability to accurately perform respiratory manoeuvres and their lack of effort in stress tests may result in erroneous estimations of the progress of disease severity.

3. Why is early detection of cognitive impairment within the respiratory assessment important?
   a) Because it averts or addresses potential safety issues.
   b) Because there are certain modifiable factors (i.e. physical activity, cognitive training and social engagement) that can be improved, presenting beneficial effects on cognitive impairment.
   c) Because it ensures that patients will have a caregiver or someone else to help them with their medical treatment.
   d) Because it allows healthcare professionals to plan long-term treatment and care.

4. Why can pulmonary rehabilitation (PR) be beneficial to cognitive impairment in COPD?
   a) Because exercise training may counteract neurological and cognitive disorders.
   b) Because patients establish social contacts, obtain support and reduce anxiety/depression, and these factors have favourable effects on cognitive impairment.
   c) Because clinical improvement has been reported in visual attention, verbal memory and visuospatial skills even after a short-term PR program (3 weeks).
   d) Because of all of the above.

Conclusions

Cognitive impairment is a prevalent limitation in patients with COPD and cognitive deficits should therefore be considered prior to healthcare planning. It is important for healthcare professionals to be aware of potential cognitive deficits in patients with COPD that could limit the effectiveness of respiratory therapy. Healthcare professionals in respiratory settings are advised to know how to administer a brief cognitive assessment test to detect COPD-related cognitive impairments when required. Early detection of cognitive impairment can prevent or delay its underlying processes and minimise potential obstacles in therapeutic strategy. COPD patients exhibiting evidence of cognitive impairment should be prioritised for participation in a comprehensive pulmonary rehabilitation programme.
Support statement

V. Andrianopoulos is the recipient of an ERS Long-Term Research Fellowship (LTRF 63-2012) and an ERS–EU RESPIRE2 Marie Sklodowska-Curie Postdoctoral Research Fellowship (MCF 8465-2015). Funding information for this article has been deposited with the Crossref Funder Registry.

Conflict of interest

None declared.

References

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2017 http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ Date last accessed: March 14 2017.
2. Hung WW, Wünschiesky JP, Siu AL, et al. Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180: 134–137.
3. Ortampak H, Naldoken S. Brain perfusion abnormalities in chronic obstructive pulmonary disease: comparison with cognitive impairment. Ann Nucl Med 2006, 20: 99–106.
4. Campbell NL, Boustani MA, Skopelja EN, et al. Medication adherence in older adults with cognitive impairment: a systematic evidence-based review. Am J Geriatr Pharmacother 2012, 10: 165–177.
5. Perneczky R, Pohl C, Sorg C, et al. Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome. Int J Geriatr Psychiatry 2006, 21: 158–162.
6. Chang SS, Chen S, McVay GJ, et al. Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults. J Am Geriatr Soc 2012, 60: 1839–1846.
7. Dodd JW. Lung disease as a determinant of cognitive decline and dementia. Alzheimers Res Ther 2015, 7: 32.
8. Torres-Sanchez I, Rodriguez-Alzueta E, Cabrera-Martos I, et al. Cognitive dysfunction in COPD: a systematic review. J Bras Pneumol 2015, 41: 182–190.
9. Dodd JW, Charlton RA, van den Broek MD, et al. Cognitive dysfunction in patients hospitalized with acute exacerbation of COPD. Chest 2013, 144: 119–127.
10. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J 2010, 35: 913–922.
11. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997, 349: 1793–1796.
12. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001, 58: 1985–1992.
13. Villeneuve S, Pepin V, Rahayel S, et al. Mild cognitive impairment in moderate to severe COPD: a preliminary study. Chest 2012; 142: 1516–1523.
14. Vanlenteren LE. Does COPD stand for "COmorbid with Pulmonary Disease"? Eur Respir J 2015, 45: 14–17.
15. Cleutjens FA, Wouters EF, Dijkstra JB, et al. The COgnitive-Pulmonary Disease (COgnitive-PD) study: protocol of a longitudinal observational comparative study on neuropsychological functioning of patients with COPD. BMJ Open 2014, 4: e004495.
16. Farrell D. Examples and principles of psychology in the bible. Enumclaw, WA, USA, Redemption Press, 2010.
17. Oxford Living Dictionaries. Definition of cognition in English. Oxford, Oxford University Press, 2017. https://en.oxforddictionaries.com/definition/cognition Date last accessed: March 14 2017.
18. Cleutjens FA, Janssen DJ, Ponds RW, et al. Cognition-Biome. Res Med Int 2014; 2014: 697825.
19. Sachdev PS, Blacker D, Blazer DG, et al. Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol 2014, 10: 634–642.
20. Cullen B, O’Neill B, Evans JJ, et al. A review of screening tests for cognitive impairment. J Neurol Neurosurg Psychiatr 2007, 78: 790–799.
21. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004, 256: 183–194.
22. Lonie JA, Tierney KM, Ebmeier KP. Screening for mild cognitive impairment: a systematic review. Int J Geriatr Psychiatry 2009, 24: 902–915.
23. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12: 189–198.
24. Mathuranath PS, Nestor PJ, Berrios GE, et al. A brief cognitive test battery to differentiate Alzheimer’s disease and frontotemporal dementia. Neurology 2000, 55: 1613–1620.
25. Moishi E, Dawson K, Mitchell J, et al. The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006, 21: 1078–1085.
26. Nasreddine ZS, Phillips NA, Bedriyan V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005, 53: 695–699.
27. Agrell B, Dehlin O. The clock-drawing test. Age Ageing 1998, 27: 399–403.
28. Borson S, Scanlan J, Brush M, et al. The mini-cog: a cognitive ‘vital signs’ measure for dementia screening in multilingual elderly. Int J Geriatr Psychiatry 2000, 15: 1021–1027.
29. Brandt J, Spencer M, Folstein M. Telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol 1988, 1: 111–118.
30. Gatz M, Reynolds CA, John R, et al. Telephone screening to identify potential dementia cases in a population-based sample of older adults. Int Psychogeriat 2002, 14: 273–289.
31. Tsio K, Chan JY, Hirai HW, et al. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med 2015, 175: 1450–1458.
32. Crews WD, Jefferson AL, Bolduc T, et al. Neuropsychological dysfunction in patients suffering from end-stage chronic obstructive pulmonary disease. Arch Clin Neuropsychol 2001, 16: 643–652.
33. Antonelli-Incalzi R, Corsonello A, Trojano L, et al. Screening of cognitive impairment in chronic obstructive pulmonary disease. Dement Geriatr Cogn Disord 2007, 23: 264–270.
34. Andreou G, Vlachos F, Makanikas K. Effects of chronic obstructive pulmonary disease and obstructive sleep apnea on cognitive functions: evidence for a common nature. Sleep Disord 2014, 2014: 768210.
35. Hall JE. Guyton and Hall Textbook of Medical Physiology. 12th Edn. Philadelphia, Saunders Elsevier, 2011; pp. 743–750.
36. Lee JM, Grabb MC, Zipfel GJ, et al. Brain tissue responses to ischemia. J Clin Invest 2000; 106: 723–731.
37. Thakur N, Blanc PD, Julian LJ, et al. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. Int J Chron Obstruct Pulmon Dis 2010, 5: 263–269.
38. Incalzi RA, Gemma A, Maria C, et al. Chronic obstructive pulmonary disease. An original model of cognitive decline. Am Rev Respir Dis 1993, 148: 418–424.
Cognitive impairment in COPD

39. Incalzi RA, Gemma A, Marra C, et al. Verbal memory impairment in COPD: its mechanisms and clinical relevance. Chest 1997; 112: 1506-1513.
40. Klein M, Gaggeal S, Sachs G, et al. Impact of chronic obstructive pulmonary disease (COPD) on attention functions. Respir Med 2010; 104: 52-60.
41. Zheng GQ, Wang Y, Wang XT. Chronic hypoxia-hypercapnia influences cognitive function: a possible new model of cognitive dysfunction in chronic obstructive pulmonary disease. Med Hypotheses 2008; 71: 111-113.
42. Liesker JJ, Postma DS, Beukema RJ, et al. Cognitive performance in patients with COPD. Respir Med 2004; 98: 351-356.
43. Van de Ven MJ, Colier WN, Van der Sluijs MC, et al. Ventilatory and cerebrovascular responses in normocapnic and hypercapnic COPD patients. Eur Respir J 2001; 18: 61-68.
44. Sartori AC, Vance DE, Slater LZ, et al. The impact of inflammation on cognitive function in older adults: implications for healthcare practice and research. J Neurosci Nurs 2012; 44: 206-217.
45. Baierle M, Nascimento SN, Moro AM, et al. Relationship between inflammation and oxidative stress and cognitive decline in the institutionalized elderly. Oxid Med Cell Longev 2015; 2015: 804198.
46. Plassman BL, Williams JW Jr, Burke JR, et al. Systematic review: factors associated with risk and possible prevention of cognitive decline in later life. Ann Intern Med 2010; 153: 182-193.
47. Foglio K, Carone M, Pagani M, et al. Physiological and symptom determinants of exercise performance in patients with chronic airway obstruction. Respir Med 2000; 94: 256-263.
48. Lee AV. Vascular dementia. Chonnam Med J 2011; 47: 66-71.
49. Reitz C, Tang MX, Manly J, et al. Hypertension and the risk of mild cognitive impairment. Arch Neurol 2007; 64: 1734-1740.
50. Duscheck S, Meinhardt J, Schandry R. Reduced cortical activity due to chronic low blood pressure: an EEG study. Biol Psychol 2006; 72: 241-250.
51. Zur D, Naftalev E, Kesler A. Evidence of multidomain mild cognitive impairment in idiopathic intracranial hypertension. J Neuroophthalmol 2015; 35: 26-30.
52. Ambrosino N, Bruletti G, Scala V, et al. Cognitive and perceived health status in patient with chronic obstructive pulmonary disease surviving acute on chronic respiratory failure: a controlled study. Intensive Care Med 2002; 28: 170-177.
53. Manswelder HD, van Aerde KL, Gouey JJ, et al. Nicotine modulation of neuronal networks: from receptors to cognition. Psychopharmacology (Berl) 2006; 184: 292-305.
54. Wollam ME, Weinstein AM, Saxton JA, et al. Genetic risk score predicts late-life cognitive impairment. J Aging Res 2015; 2015: 267062.
55. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 2014; 69, Suppl. 1: S4-S9.
56. Strandgaard S, Paulson OB. Cerebrovascular consequences of hypertension. Lancet 1994; 344: 519-521.
57. Duscheck S, Matthias E, Schandry R. Essential hypertension is accompanied by deficits in attention and working memory. Behav Med 2005; 30: 149-158.
58. Andreassi JL. Psychophysiology: human behavior and physiological response. Int J Psychophysiol 2007; 65: 174-175.
59. Hamel R, Ramakers I, Oosterveld S, et al. The influence of comorbidities on cognitive decline and conversion to dementia with mild cognitive impairment. Alzheimers & Dementia 2014; 10: P139.
60. Flint J. Genetic basis of cognitive disability. Dialogues Clin Neurosci 2001; 3: 37-46.
61. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009; 66: 1447-1455.

62. Carvalheira-Neto N, Lorino H, Gallinari C, et al. Cognitive function and assessment of lung function in the elderly. Am J Respir Crit Care Med 1995; 152, Issue 5, pt. 1: 1611-1615.
63. Tang A, Eng JJ, Tsang TS, et al. Cognition and motor impairment correlates with exercise test performance after stroke. Med Sci Sports Exerc 2013; 45: 622-627.
64. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008; 63: 831-838.
65. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 371-384.
66. Appelbaum PS, Roth LH. Patients who refuse treatment in medical hospitals. JAMA 1983; 250: 1296-1301.
67. Coutts JA, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child 1992; 67: 332-333.
68. Yu F, Evans LK, Sullivan-Marx EM. Functional outcomes for older adults with cognitive impairment in a comprehensive outpatient rehabilitation facility. J Am Geriatr Soc 2005; 53: 1599-1606.
69. Tabert MH, Albert SM, Borukhova-Milov L, et al. Functional deficits in patients with mild cognitive impairment: prediction of AD. Neurology 2002; 58: 758-764.
70. Woodford HJ, George J. Cognitive assessment in the elderly: a review of clinical methods. QJM 2007; 100: 469-484.
71. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med 2009; 39: 3-11.
72. Blondell SJ, Hammerness-Mather R, Veerman JL. Does physical activity prevent cognitive decline and dementia? A systematic review and meta-analysis of longitudinal studies. BMC Public Health 2014; 14: 510.
73. Agrawal R, Gomez-Pinilla F. 'Metabolic syndrome' in the brain: deficiency in omega-3 fatty acid exacerbates dysfunctions in insulin receptor signalling and cognition. J Physiol 2012; 590: 2485-2499.
74. Martin M, Clare L, Altgassen AM, et al. Cognition-based interventions for healthy older people and people with mild cognitive impairment. Cochrane Database Syst Rev 2011; CD006220.
75. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004; 3: 343-353.
76. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13-e64.
77. Gomez-Pinilla F, Hillman C. The influence of exercise on cognitive abilities. Compr Physiol 2013; 3: 403-428.
78. Hill K, Vogiatzis I, Burtin C. The importance of components of pulmonary rehabilitation, other than exercise training, in COPD. Eur Respir Rev 2013; 22: 405-413.
79. Tselebis A, Bratis D, Pachi A, et al. A pulmonary rehabilitation program reduces levels of anxiety and depression in COPD patients. Multiscip Respir Rev 2013; 8: 41.
80. Spielmanns M, Gloeckl R, Schmoor C, et al. Effects on pulmonary rehabilitation in patients with COPD or ILD: a retrospective analysis of clinical and functional predictors with particular emphasis on gender. Respir Med 2016; 113: 8-14.
81. Kren K, Gloeckl R, Soenichsen A, et al. Predictors of success for pulmonary rehabilitation in patients awaiting lung transplantation. Transplantation 2015; 99: 1072-1077.
82. Pereira ED, Viana CS, Taunay TC, et al. Improvement of cognitive function after a three-month pulmonary rehabilitation program for COPD patients. Lung 2011; 189: 279-285.
83. Kozora E, Tran ZV, Make B. Neurobehavioral improvement after brief rehabilitation in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2002; 22: 426-430.
84. Karamanli H, Ilik F, Kayhan F, et al. Assessment of cognitive impairment in long-term oxygen therapy-dependent COPD patients. Int J Chron Obstruct Pulmon Dis 2015; 10: 2087-2094.